Jpmorgan Chase & CO Neuronetics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Neuronetics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 34 shares of STIM stock, worth $99. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34
Previous 54,939
99.94%
Holding current value
$99
Previous $81,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding STIM
# of Institutions
96Shares Held
18.6MCall Options Held
49.6KPut Options Held
78.8K-
Vanguard Group Inc Valley Forge, PA2.74MShares$8.01 Million0.0% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.74MShares$5.08 Million1.44% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.51MShares$4.41 Million0.01% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.1MShares$3.21 Million1.17% of portfolio
-
Masters Capital Management LLC Atlanta, GA1MShares$2.92 Million0.14% of portfolio
About Neuronetics, Inc.
- Ticker STIM
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 27,022,800
- Market Cap $78.9M
- Description
- Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive diso...